Latest News on Usfda
Showing of 0 - 10 from 93 results
Usfda - Total results - 93
Jul 16, 2019
Where is India’s pharma market headed? Regulatory infrastructure must be put in place to ensure global qualityThe pace at which the “pharmacy of the world” is growing, there’s no denying that India is utilising its full potential.
Jul 15, 2019
Indoco Remedies gets warning letter from USFDA for oral dosages plant in Goa; share price down 5.91%Drug firm Indoco Remedies on Monday said it has received a warning letter from the US health regulator for its oral dosages facility in Goa
May 27, 2019
Lupin shares fall 2.5% after USFDA says Goa facility may be subject to regulatory actionThe scrip declined 2.49 percent to close at Rs 743.95 on the BSE. During the day, it dropped 5.43 percent to Rs 721.50
Apr 12, 2019
Ranbaxy promoters Malvinder, Shivinder Singh diverted funds despite order to maintain stakes, Daiichi Sankyo tells SCThe Supreme Court had earlier expressed displeasure at the replies of Malvinder and Shivinder to its directive to submit a plan for paying Rs 4,000 crore to Daiichi Sankyo, as awarded by a Singapore tribunal.
Mar 22, 2019
Jubilant Life's Nanjangud facility may face regulatory action by USFDA; firm says announcement not to impact revenuesJubilant Life Sciences said USFDA's announcement will not have any impact on the existing revenues from operations of this facility.
Mar 14, 2019
Zydus Cadila gets USFDA nod to market generic anti-diabetic drugDrug firm Zydus Cadila Thursday said it has received tentative nod from the US health regulator to market generic Sitagliptin and Metformin Hydrochloride extended-release tablets used for controlling blood sugar levels
Mar 12, 2019
Zydus Cadila gets USFDA nod to market blood pressure lowering drug in the USDrug firm Zydus Cadila on Tuesday said it has received final approval from the US health regulator to market Atenolol and Chlorthalidone tablets USP, used to treat high blood pressure, in the US
Dec 10, 2018
Lupin gets Establishment Inspection Report from USFDA for Pithampur facility unit; stock falls 1.88%Drug firm Lupin on Monday said it has received an Establishment Inspection Report (EIR) from the US health regulator for a unit of its Pithampur facility in Madhya Pradesh.
Nov 27, 2018
Lupin gets observation in establishment inspection report from USFDA for Tarapur facilityShares of Lupin were trading at Rs 854.00 per scrip on the BSE, up 1.09 percent from its previous close.
Nov 21, 2018
Decks cleared for resuming launch of Dr Reddy’s generic Suboxone after US court rejects rival firm’s patent breach caseThe US Court of Appeals for the Federal Circuit concluded that Indivior had not shown that it is likely to succeed on the merits of its infringement case.